Shares Magazine
37.40p+0.30 (+0.81%)23 Aug 2024, 16:40
Jump to:
Alliance Pharma PLC Fundamentals
| Company Name | Alliance Pharma PLC | Last Updated | 2024-08-23 |
|---|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Sector | Healthcare |
| Shares in Issue | 540.566 m | Market Cap | £202.17 m |
| PE Ratio | 285.71 | Dividend per Share | £0.01 |
| Dividend Yield | 0 | Dividend Cover | 0 |
| EPS | -£0.06 | EPS Growth (%) | 0 |
| PEG | 0 | DPS Growth (%) | -0.3116 |
| Debt Ratio | 0.2830 | Debt Equity Ratio | 0.5354 |
| Asset Equity Ratio | 1.9044 | Cash Equity Ratio | 0.1030 |
| Quick Ratio | 1.8270 | Current Ratio | 2.57 |
| Price To Book Value | 0.9279 | ROCE | 0 |
Alliance Pharma PLC Dividends
| Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
|---|---|---|---|---|---|
| Prelim | 2023-06-22 | 2023-07-18 | GBP | 0.0118 | |
| Interim | 2022-12-22 | 2023-01-19 | GBP | 0.0059 | |
| Prelim | 2022-06-09 | 2022-07-07 | GBP | 0.0113 | |
| Interim | 2021-12-16 | 2022-01-07 | GBP | 0.0056 |
Alliance Pharma PLC Company Financials
| Assets | 2023 | 2022 | 2021 |
|---|---|---|---|
| Tangible Assets | £5.72 m | £5.58 m | £4.83 m |
| Intangible Assets | £299.98 m | £393.37 m | £413.74 m |
| Investments | 0 | 0 | 0 |
| Total Fixed Assets | £310.83 m | £403.67 m | £422.47 m |
| Stocks | £25.71 m | £24.29 m | £21.07 m |
| Debtors | £51.69 m | £48.23 m | £30.82 m |
| Cash & Equivalents | £22.44 m | £31.71 m | £29.06 m |
| Other Assets | 0 | 0 | 0 |
| Total Assets | £414.92 m | £509.15 m | £503.49 m |
| Liabilities | 2023 | 2022 | 2021 |
|---|---|---|---|
| Creditors within 1 year | £40.57 m | £47.02 m | £40.58 m |
| Creditors after 1 year | £156.48 m | £196.61 m | £180.43 m |
| Other Liabilities | 0 | 0 | 0 |
| Total Liabilities | £197.05 m | £243.64 m | £221.00 m |
| Net assets | £217.87 m | £265.52 m | £282.49 m |
| Equity | 2023 | 2022 | 2021 |
|---|---|---|---|
| Called up share capital | £5.40 m | £5.40 m | £5.38 m |
| Share Premium | £151.68 m | £151.65 m | £151.33 m |
| Profit / Loss | -£48.80 m | -£23.05 m | £18.16 m |
| Other Equity | £217.87 m | £265.52 m | £282.49 m |
| Preference & Minorities | 0 | 0 | 0 |
| Total Capital Employed | £217.87 m | £265.52 m | £282.49 m |
| Ratios | 2023 | 2022 | 2021 |
|---|---|---|---|
| Debt Ratio | £0.35 | £0.34 | £0.30 |
| Debt-to-Equity | £0.54 | £0.52 | £0.42 |
| Assets / Equity | 1.9044 | 1.9044 | 1.9044 |
| Cash / Equity | 0.1030 | 0.1030 | 0.1030 |
| EPS | £0.05 | -£0.01 | £0.01 |
| Cash Flow | 2023 | 2022 | 2021 |
|---|---|---|---|
| Cash from operating activities | £31.41 m | £20.97 m | £38.66 m |
| Cashflow before financing | -£7.78 m | £20.10 m | £4.32 m |
| Increase in Cash | -£8.70 m | £3.07 m | -£284,000.00 |
| Income | 2023 | 2022 | 2021 |
|---|---|---|---|
| Turnover | £180.68 m | £167.42 m | £163.21 m |
| Cost of sales | £75.66 m | £65.73 m | £53.76 m |
| Gross Profit | £105.02 m | £101.68 m | £109.45 m |
| Operating Profit | -£38.44 m | -£17.69 m | £21.57 m |
| Pre-Tax profit | -£48.80 m | -£23.05 m | £18.16 m |
Alliance Pharma PLC Company Background
| Sector | Healthcare |
|---|---|
| Activities | Alliance Pharma PLC is a player in the healthcare market. The company's business includes the acquisition, marketing, and distribution of consumer healthcare and pharmaceutical products. The group operates in two segments: Consumer Healthcare brands and Prescription Medicines. The company generates the majority of its revenue from the Consumer Healthcare segment. The products of the company include Aloclair, Biodermatin, Changmin, Decapional, Effadiane, Fazol, and others. Geographically, the company derives a majority of its revenue from Europe, the Middle East, and Africa (EMEA). |
| Latest Interim Date | 26 Sep 2023 |
| Latest Fiscal Year End Date | 19 Jun 2024 |
Alliance Pharma PLC Directors
| Appointed | Name | Position |
|---|---|---|
| 2014-12-30 | Mr. Paul Ranson | Non-Executive Director |
| 2018-03-01 | Mr. Andrew Leonard Smith | Non-Executive Director,Chairman |
| 2014-05-23 | Mr. Michael Richard Brock Gatenby | Non-Executive Director,Chairman |
| 2015-05-29 | Mr. Richard David Wright | Executive Director,Finance Director |
| 2019-07-01 | Mr. John Dawson | Non-Executive Director |
| 2021-04-15 | Mr. Nigel Richard Clifford | Non-Executive Director |
| 2019-04-25 | Mr. Anthony Richard Booley | Executive Director,Sales and Marketing Director |
| 2019-04-16 | Mr. Thomas Theodore Casdagli | Non-Executive Director |
| 2024-05-13 | Mr. Peter Jonathan Butterfield | Executive Director,Chief Executive Officer |
| 2006-12-31 | Ms. Stella Anne Dawson BSc,MSc | Executive Director,Acquisition Integration Director |
| 2006-12-31 | Ms. Madeleine Elizabeth Scott ACCA,ACIS | Executive Director,Finance Director and Company Secretary |
| 2011-08-09 | Dr. Mark John Tomlinson MB,BCh,MRCGP | Executive Director,Medical Director |
| 2023-03-23 | Mr. David John Cook | Non-Executive Director,Chairman |
| 2024-06-19 | Mr. Andrew Timothy Franklin | Executive Director,Finance Director |
| 2024-06-19 | Mr. Richard Crispin Morgan Jones | Non-Executive Director,Senior Independent Director |
| 2024-02-19 | Ms. Joanna Susan Le Couilliard | Non-Executive Director,Chairman |
| 2024-07-31 | Mr. Jeyan Heper | Executive Director,Chief Operating Officer |
| 2024-06-27 | Mr. Nicholas John Sedgwick | Executive Director,Chief Executive Officer |
Alliance Pharma PLC Contact Details
| Company Name | Alliance Pharma PLC |
|---|---|
| Address | Bath Road, Avonbridge House, Chippenham, SN15 2BB |
| Telephone | +44 1249466966 |
| Website | https://www.alliancepharmaceuticals.com |
Alliance Pharma PLC Advisors
| Auditor | KPMG |
|---|---|
| Phone | +44 01179054000 |
| Fax | +44 01179054001 |
| Bank | Silicon Valley Bank |
|---|
| Bank | Royal Bank of Scotland PLC |
|---|
| Nominated Adviser | Numis Securities Limited |
|---|---|
| Phone | +44 2072601000 |
| Fax | +44 2072601001 |
| Registrar | Capita Asset Services |
|---|---|
| Phone | +44 8716640300 |
| Fax | +44 2086392342 |
| Stockbroker | Numis Securities Limited |
|---|---|
| Phone | +44 2072601000 |
| Bank | Lloyds Bank PLC |
|---|
| Financial PR Adviser | Buchanan |
|---|---|
| Phone | +44 2074665000 |
| Fax | +44 2074665001 |
| Solicitor | Fasken Martineau LLP |
|---|---|
| Phone | (020) 7917 8500 |
| Fax | (020) 7917 8555 |
| Auditor | Grant Thornton UK LLP |
|---|---|
| Phone | +44 2073835100 |
| Fax | +44 2073834715 |
Receive our
daily news email
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
Market Overview
UK 350 Risers and Fallers
Risers
| Company | Price | % Chg |
|---|---|---|
| Jd Sports Fashion PLC | 149.25 | 5.22 |
| Hammerson PLC | 28.98 | 3.43 |
| B&M European Value Retail S.A. | 452.50 | 3.08 |
| Ithaca Energy PLC | 127.60 | 3.07 |
| Supermarket Income Reit PLC | 76.00 | 2.70 |
| Carnival PLC | 1,110.50 | 2.68 |
Fallers
| Company | Price | % Chg |
|---|---|---|
| Melrose Industries PLC | 474.70 | -7.10 |
| Renishaw PLC | 3,520.00 | -3.03 |
| Hays PLC | 95.25 | -2.21 |
| Bh Macro Limited | 362.50 | -2.03 |
| Direct Line Insurance Group PLC | 185.20 | -2.01 |
| Sage Group PLC | 996.20 | -2.00 |
Risers/fallers data from previous trading day.